Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen L Chan

Showing results (141-150 of 164) with videos related to

Pageof 17
Sort By:
Cell Genomics|February 7, 2026
Holistic determination of ends of cfDNA moleculesPeiyong Jiang, Mary-Jane L Ma, Rong Qiao, et al.
Journal of Hepatology|April 13, 2025
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCCLorenza Rimassa, Stephen L Chan, Bruno Sangro, et al.
Cancer|May 7, 2015
Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinomaEdwin P Hui, Brigette B Y Ma, K C Allen Chan, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 26, 2022
Epigenetic analysis of cell-free DNA by fragmentomic profilingQing Zhou, Guannan Kang, Peiyong Jiang, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 23, 2015
Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessmentsKun Sun, Peiyong Jiang, K C Allen Chan, et al.
Future Oncology (London, England)|September 6, 2023
Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)Ghassan K Abou-Alfa, George Lau, Masatoshi Kudo, et al.
Lancet (London, England)|July 27, 2023
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 studyShukui Qin, Stephen L Chan, Shanzhi Gu, et al.
NEJM Evidence|February 6, 2024
Tremelimumab plus Durvalumab in Unresectable Hepatocellular CarcinomaGhassan K Abou-Alfa, George Lau, Masatoshi Kudo, et al.
NEJM Evidence|February 6, 2024
Plasma Epstein-Barr Virus DNA and Risk of Future Nasopharyngeal CancerK C Allen Chan, W K Jacky Lam, Ann King, et al.
Lancet (London, England)|January 11, 2025
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 studyBruno Sangro, Masatoshi Kudo, Joseph P Erinjeri, et al.
Pageof 17

Showing results (141-150 of 164) with videos related to

Sort By:
Pageof 17
Cell Genomics|February 7, 2026
Holistic determination of ends of cfDNA moleculesPeiyong Jiang, Mary-Jane L Ma, Rong Qiao, et al.
Journal of Hepatology|April 13, 2025
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCCLorenza Rimassa, Stephen L Chan, Bruno Sangro, et al.
Cancer|May 7, 2015
Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinomaEdwin P Hui, Brigette B Y Ma, K C Allen Chan, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 26, 2022
Epigenetic analysis of cell-free DNA by fragmentomic profilingQing Zhou, Guannan Kang, Peiyong Jiang, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 23, 2015
Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessmentsKun Sun, Peiyong Jiang, K C Allen Chan, et al.
Future Oncology (London, England)|September 6, 2023
Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)Ghassan K Abou-Alfa, George Lau, Masatoshi Kudo, et al.
Lancet (London, England)|July 27, 2023
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 studyShukui Qin, Stephen L Chan, Shanzhi Gu, et al.
NEJM Evidence|February 6, 2024
Tremelimumab plus Durvalumab in Unresectable Hepatocellular CarcinomaGhassan K Abou-Alfa, George Lau, Masatoshi Kudo, et al.
NEJM Evidence|February 6, 2024
Plasma Epstein-Barr Virus DNA and Risk of Future Nasopharyngeal CancerK C Allen Chan, W K Jacky Lam, Ann King, et al.
Lancet (London, England)|January 11, 2025
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 studyBruno Sangro, Masatoshi Kudo, Joseph P Erinjeri, et al.
Pageof 17